Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Drug

Neuboron Medtech Secures Clinical Trial Approval for First BNCT Drug in China

Fineline Cube Jan 16, 2024

Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b)...

Company

AstraZeneca China Announces Leadership Changes and New Biopharmaceutical Unit

Fineline Cube Jan 16, 2024

AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the...

Company Drug

SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer

Fineline Cube Jan 16, 2024

SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...

Policy / Regulatory

China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy

Fineline Cube Jan 16, 2024

The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...

Company Deals

China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million

Fineline Cube Jan 16, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...

Company Drug

Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure

Fineline Cube Jan 16, 2024

Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase...

Company Drug

CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine

Fineline Cube Jan 16, 2024

CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of...

Company Deals

Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline

Fineline Cube Jan 16, 2024

Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...

Company Deals

Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success

Fineline Cube Jan 16, 2024

Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...

Company Drug

RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer

Fineline Cube Jan 16, 2024

China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...

Company Drug

CSPC Pharmaceutical Secures FDA Approval for Clinical Study of JMT106 in GPC3-Positive Tumors

Fineline Cube Jan 16, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to...

Company Deals

BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs

Fineline Cube Jan 15, 2024

Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC)...

Company Deals

NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference

Fineline Cube Jan 15, 2024

At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a...

Company Deals

Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis

Fineline Cube Jan 15, 2024

Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...

Company Drug

MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment

Fineline Cube Jan 15, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...

Company Deals

Boai NKY Medical Holdings Partners with HuaDao Biopharma for CAR-T Therapy Incubator

Fineline Cube Jan 15, 2024

Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic...

Policy / Regulatory

China’s NHSA Unveils Measures to Secure Volume-Based Procurement Supply

Fineline Cube Jan 15, 2024

The National Healthcare Security Administration (NHSA) has issued a notification outlining key measures to ensure...

Company Drug

BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan

Fineline Cube Jan 15, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy...

Company Deals

Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion

Fineline Cube Jan 15, 2024

EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of...

Company Deals

Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer

Fineline Cube Jan 15, 2024

Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...

Posts pagination

1 … 352 353 354 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.